How Liquid Biopsy Works—and Why It Could Change Cancer Detection

A Blood Draw Instead of a Scalpel

For decades, detecting cancer has meant waiting for symptoms, then cutting out a piece of tissue for examination under a microscope. Liquid biopsy promises something radically different: a simple blood test that catches cancer early—potentially before a tumor is even visible on a scan.

The concept rests on a biological fact. When cells die, they release tiny fragments of their DNA into the bloodstream. Cancer cells do the same, shedding what scientists call circulating tumor DNA (ctDNA). A liquid biopsy captures and analyzes these fragments, reading their genetic and chemical signatures to determine whether cancer is present—and often where in the body it originated.

The Science Behind the Test

Every cell in the human body sheds DNA as it ages and dies. These fragments, collectively called cell-free DNA (cfDNA), float through the bloodstream in pieces roughly 140–170 base pairs long—about the length wrapped around a single nucleosome, the spool-like protein that packages DNA.

In a healthy person, most cfDNA comes from normal blood cells. In a cancer patient, a small fraction comes from the tumor. The challenge is finding that fraction: in early-stage cancers, ctDNA may represent less than 0.01% of all cell-free DNA in the blood.

Modern liquid biopsies use advanced sequencing techniques to spot the difference. Some look for genetic mutations unique to tumors. Others analyze methylation patterns—chemical tags on DNA that differ between healthy and cancerous cells. Methylation-based approaches have proven especially useful for multi-cancer screening because different cancer types leave distinct methylation fingerprints, allowing the test to predict the tissue of origin.

From One Cancer to Fifty

Traditional screening tests target individual cancers: mammograms for breast, colonoscopies for colon, PSA tests for prostate. But most of the 200-plus cancer types have no routine screening at all.

Multi-cancer early detection (MCED) tests aim to change that. The most prominent, Grail's Galleri test, screens for signals shared by more than 50 cancer types from a single blood draw. A large UK trial enrolling over 140,000 asymptomatic participants found that sequential screening rounds reduced Stage IV diagnoses of the deadliest cancers by more than 20%, according to analysis of the trial results.

Meanwhile, UCLA researchers recently unveiled MethylScan, a lower-cost alternative that analyzes cfDNA methylation to detect multiple cancers, liver diseases, and organ abnormalities simultaneously—achieving 63% sensitivity at 98% specificity in early studies.

What Liquid Biopsy Cannot Do Yet

The technology faces real limitations. Early-stage tumors shed very little DNA, making detection hardest precisely when it matters most. The biological noise is significant: clonal hematopoiesis of indeterminate potential (CHIP)—age-related mutations in blood cells that mimic cancer signals—can trigger false positives, sending healthy patients down an anxiety-inducing diagnostic path.

Overdiagnosis is another concern. Some cancers, particularly indolent thyroid tumors, may never threaten a patient's life. Detecting them could lead to unnecessary treatments without improving survival. Standardization also remains a hurdle: different labs using different collection methods and sequencing platforms can produce variable results.

As of early 2026, no MCED test has received full regulatory approval as a screening device from any major global authority, and clinical guidelines do not yet recommend them as replacements for standard screening, according to the American Society of Clinical Oncology.

Beyond Screening

Cancer detection is only one application. Liquid biopsy is already used clinically to guide treatment decisions—identifying actionable mutations when a tissue biopsy is too risky or impractical. It can monitor whether a therapy is working by tracking ctDNA levels over time and detect minimal residual disease (MRD), the tiny traces of cancer that remain after surgery and predict relapse.

The MCED testing market is projected to reach $7.52 billion by 2033. In the United States, legislation signed into law authorizes Medicare to cover FDA-approved MCED tests starting in 2028.

The Bottom Line

Liquid biopsy will not replace mammograms or colonoscopies overnight. But as sensitivity improves and costs fall, blood-based cancer screening could fill the vast gap where no screening exists at all—catching cancers that today are found only after they spread. The blood, it turns out, has been carrying the evidence all along.